胰腺导管腺癌影像检查漏诊或误判的影响:一项多中心人群研究
该研究基于新斯科舍省癌症登记处2014-2015年诊断的257例胰腺导管腺癌患者,由两名放射科医生独立用RADPEER系统对诊断间期内的超声、CT和MRI检查评分,评估漏诊/误判比例及其与诊断间期和生存的关系。结果显示25.7%的患者影像已显示病变但被漏诊或误判,RADPEER 3组诊断间期显著长于RADPEER 1和2组,但影像相关延迟与生存无关,可能因队列总体生存极差。
要点
- 约四分之一(66/257,25.7%)的胰腺导管腺癌患者影像已显示病变但被漏诊或误判。
- RADPEER 2和3分别占10.5%和15.2%,RADPEER 3组诊断间期(192±323天)显著长于RADPEER 1组(53±86天)和RADPEER 2组(86±120天)(p<0.001)。
- 影像相关诊断延迟未与更差生存相关,但可能受队列总体生存极差(仅3/257,1.2%存活)混杂。
诊断标准与关键数值
- RADPEER 1-3评分分别分配给191、27和39例患者。
- RADPEER 3组诊断间期192±323天,显著长于RADPEER 1组53±86天和RADPEER 2组86±120天(p<0.001)。
- 平均生存率在RADPEER组间无差异(p=0.43)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文指出影像相关诊断延迟未与更差生存相关,但可能受队列总体生存极差(仅3/257,1.2%存活)混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess the proportion of missed/misinterpreted imaging examinations of pancreatic ductal adenocarcinoma (PDAC), and their association with the diagnostic interval and survival.
METHODS: Two hundred fifty-seven patients (mean age, 71.8 years) diagnosed with PDAC in 2014-2015 were identified from the Nova Scotia Cancer Registry. Demographics, stage, tumor location, and dates of initial presentation, diagnosis, and, if applicable, surgery and death were recorded. US, CT, and MRI examinations during the diagnostic interval were independently graded by two radiologists using the RADPEER system; discordance was resolved in consensus. Mean diagnostic interval and survival were compared amongst RADPEER groups (one-way ANOVA). Kaplan-Meier analysis was performed for age (< 65, 65-79, ≥ 80), sex, tumor location (proximal/distal), stage (I-IV), surgery (yes/no), chemotherapy (yes/no), and RADPEER score (1-3). Association between these covariates and survival was assessed (multivariate Cox proportion hazards model).
RESULTS: RADPEER 1-3 scores were assigned to 191, 27, and 39 patients, respectively. Mean diagnostic intervals were 53, 86, and 192 days, respectively (p = 0.018). There were only 3/257 (1.2%) survivors. Mean survival was not different between groups (p = 0.43). Kaplan-Meier analysis showed worse survival in RADPEER 1-2 (p = 0.007), older age (p < 0.001), distal PDAC (p = 0.016), stage (p < 0.0001), and no surgery (p < 0.001); survival was not different with sex (p = 0.083). Cox analysis showed better survival in RADPEER 3 (p = 0.005), women (p = 0.002), surgical patients (p < 0.001), and chemotherapy (p < 0.001), and worse survival in stage IV (p = 0.006).
CONCLUSION: Imaging-related delays occurred in one-fourth of patients and were associated with longer diagnostic intervals but not worse survival, potentially due to overall poor survival in the cohort.
KEY POINTS: • One-fourth of patients (66/257, 25.7%) with pancreatic ductal adenocarcinoma (PDAC) underwent imaging examinations that demonstrated manifestations of the disease, but findings were either missed or misinterpreted; RADPEER 2 and 3 scores were assigned to 10.5% and 15.2% of patients, respectively. • Patients with imaging examinations assigned RADPEER 3 scores were associated with significantly longer diagnostic intervals (192 ± 323 days) than RADPEER 1 (53 ± 86 days) and RADPEER 2 (86 ± 120 days) (p < 0.001). • Imaging-related diagnostic delays were not associated with worse survival; however, this may have been confounded by the overall poor survival in our cohort (only 3/257 (1.2%) survivors).
引用
- Kang J, Clarke SE, Abdolell M, et al. The implications of missed or misinterpreted cases of pancreatic ductal adenocarcinoma on imaging: a multi-centered population-based study. Eur Radiol. 2020. PMID: 32785768. doi:10.1007/s00330-020-07120-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。